X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to discover small molecule drug candidates against Lilly's undisclosed targets.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 16, 2024
Details:
The net proceeds will be used for the advancement of company's pipeline of clinical candidates led by TOS-358, a covalent inhibitor of PI3Ka for the treatment of adults with select solid tumors.
Lead Product(s): TOS-358
Therapeutic Area: Oncology Product Name: TOS-358
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: DCVC Bio
Deal Size: $66.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 15, 2023
Details:
TOS-358 is the company's first-in-class covalent, highly specific, potent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations.
Lead Product(s): TOS-358
Therapeutic Area: Oncology Product Name: TOS-358
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
TOS-358 is a highly selective covalent inhibitor of PI3Kα. TOS-358 demonstrates clear superiority compared to non-covalent molecules by achieving deep and durable inhibition of PI3K-AKT signaling.
Lead Product(s): TOS-358
Therapeutic Area: Oncology Product Name: TOS-358
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
TOS-358, the first highly selective covalent molecule targeting PI3Kα, which is the most mutated oncogene in cancer, induces stasis and regression across PI3Kα mutant models.
Lead Product(s): TOS-358
Therapeutic Area: Oncology Product Name: TOS-358
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
The Series A financing will be used to expand and scale Totus Medicines' proprietary drug discovery platform and advance the company's TOS-358 drug program targets the PI3K? mutation into the clinic.
Lead Product(s): TOS-358
Therapeutic Area: Oncology Product Name: TOS-358
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: DCVC Bio
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
